Ifosfamide

Generic Name
Ifosfamide
Brand Names
Ifex
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
3778-73-2
Unique Ingredient Identifier
UM20QQM95Y
Background

Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

Indication

Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indi...

Associated Conditions
Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma
Associated Therapies
-
Clinical Trials
Related News

A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

First Posted Date
2023-02-03
Last Posted Date
2024-03-20
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT05711628

A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma

Phase 1
Not yet recruiting
Conditions
Osteosarcoma
Interventions
Drug: Etoposide
Drug: Sulfatinib
Drug: Isophosphamide
First Posted Date
2022-10-21
Last Posted Date
2022-10-21
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
148
Registration Number
NCT05590572
Locations
🇨🇳

Peking University People's Hospital, Beijing, Beijing, China

🇨🇳

Qilu Hospital of Shandong University, Jinan, Shandong, China

🇨🇳

Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

and more 2 locations

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

First Posted Date
2022-09-09
Last Posted Date
2024-12-16
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
65
Registration Number
NCT05533775
Locations
🇧🇷

Hospital Erasto Gaertner, Curitiba, Brazil

🇧🇷

GRAACC - Grupo de Apoio ao Adolescente e a Crianca com Cancer, Sao Paulo, Brazil

🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

and more 21 locations

A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma

First Posted Date
2022-05-06
Last Posted Date
2024-12-19
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
40
Registration Number
NCT05364424
Locations
🇺🇸

Chao Family Comprehensive Cancer Center UCI, Orange, California, United States

🇺🇸

Memorial Cancer Institute at Memorial West, Pembroke Pines, Florida, United States

🇺🇸

The University of Chicago, Chicago, Illinois, United States

and more 6 locations

Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

First Posted Date
2022-02-03
Last Posted Date
2024-12-05
Lead Sponsor
University of Southampton
Target Recruit Count
65
Registration Number
NCT05221645
Locations
🇬🇧

Oxford Cancer & Haematology Centre, The Churchill Hospital, Headington, Oxford, United Kingdom

🇬🇧

The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma

First Posted Date
2021-07-29
Last Posted Date
2023-04-12
Lead Sponsor
St. Petersburg State Pavlov Medical University
Target Recruit Count
30
Registration Number
NCT04981899
Locations
🇷🇺

St. Petersburg State Pavlov Medical University, Saint Petersburg, Russian Federation

🇷🇺

Irkutsk Regional Cancer Center, Irkutsk, Russian Federation

🇷🇺

National Medicine Research Center of oncology named after N.N. Petrov, Saint Petersburg, Pesochny, Russian Federation

Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)

First Posted Date
2021-07-20
Last Posted Date
2023-03-03
Lead Sponsor
Institut Bergonié
Target Recruit Count
66
Registration Number
NCT04968106
Locations
🇫🇷

Institut Bergonié, Bordeaux, France

🇫🇷

Centre Léon Bérard, Lyon, France

🇫🇷

Institut Curie, Paris, France

and more 1 locations

A Study of N9 Chemotherapy in Children With Neuroblastoma

First Posted Date
2021-07-01
Last Posted Date
2024-12-02
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
26
Registration Number
NCT04947501
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

First Posted Date
2021-04-06
Last Posted Date
2023-10-12
Lead Sponsor
GWT-TUD GmbH
Target Recruit Count
334
Registration Number
NCT04833114
Locations
🇩🇪

Universitätsklinikum Jena, Jena, Germany

🇩🇪

Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

🇩🇪

DIAKO Ev.Diakonie-Krankenhaus gemeinnützige GmbH, Bremen, Germany

and more 61 locations

Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma

Phase 2
Recruiting
Conditions
Soft Tissue Sarcoma
Interventions
Drug: Ifosfamide
Drug: Doxorubicin
First Posted Date
2021-03-01
Last Posted Date
2024-04-15
Lead Sponsor
Oslo University Hospital
Target Recruit Count
49
Registration Number
NCT04776525
Locations
🇳🇴

Haukeland University Hospital, Bergen, Norway

🇳🇴

Oslo University Hospital, Oslo, Norway

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy